To hear about similar clinical trials, please enter your email below
Trial Title:
Test of CD47-SIRPα Inhibitors on the Immune Microenvironment Colon Cancer
NCT ID:
NCT05955196
Condition:
Cancer of the Colon
Conditions: Official terms:
Colonic Neoplasms
Study type:
Observational [Patient Registry]
Overall status:
Recruiting
Study design:
Time perspective:
Prospective
Intervention:
Intervention type:
Procedure
Intervention name:
BLOOD AND TUMOR
Description:
sampling of 24 ml of peripheral blood and samples of colon cancers with healthy tissue in
parallel on the surgery piece
Summary:
Our goal is to create novel CD47-SIRPα inhibitors using small molecules to reverse
TAM-mediated immune suppression and restore anti-tumor immunity in CRCs. Our program uses
structure-based drug design to create selective and potent small molecule inhibitors of
SIRPα-CD47 to target the tumor microenvironment with greater efficacy and lower toxicity
than CD47-targeting antibodies. .
In order to study the activity of CD47-SIRPα inhibitors on the immune microenvironment of
tumors, we propose to use organoids derived from biopsies of patients with colon cancer.
Tumoroids preserve the patient's tumor stroma (including myeloid cells) and provide an
accurate in vitro model of complex tumor immune interaction for the evaluation of
immunotherapies.
Criteria for eligibility:
Study pop:
The population studied concerns patients over the age of 18, suffering from colon cancer,
undergoing immediate surgery or after chemotherapy.
Sampling method:
Non-Probability Sample
Criteria:
Inclusion Criteria:
- Patient over 18 years old
- Patient who has signed a consent to participate;
- Patient with metastatic or non-metastatic colon cancer, or recurrence of colon
cancer for whom excision surgery has been proposed;
- Patient affiliated to a social security scheme, or beneficiary of such a scheme
Exclusion Criteria:
- Patient who had emergency colon cancer surgery
- Person in an emergency situation or unable to express their consent.
- Adult subject to a legal protection measure (adult under guardianship, curatorship
or safeguard of justice),
- Patient unable to submit to the medical follow-up of the trial for geographical,
social or psychological reasons
Gender:
All
Minimum age:
18 Years
Maximum age:
N/A
Healthy volunteers:
No
Locations:
Facility:
Name:
Institut Paoli Calmettes
Address:
City:
Marseille
Zip:
13009
Country:
France
Status:
Recruiting
Contact:
Last name:
GENRE Dominique
Contact backup:
Phone:
33 (0)4 91 22 37 78
Email:
drci.up@ipc.unicancer.fr
Start date:
January 9, 2023
Completion date:
January 9, 2027
Lead sponsor:
Agency:
Institut Paoli-Calmettes
Agency class:
Other
Source:
Institut Paoli-Calmettes
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT05955196
